Syndax Pharmaceuticals (SNDX)
Markets targeted therapies for acute leukemias and chronic graft-versus-host disease.
Something off on this page? Send us feedback.
Markets Revuforj for genetically defined relapsed or refractory acute leukemias and shares U.S. economics on Niktimvo for chronic graft-versus-host disease with Incyte. Revenue comes from direct Revuforj sales and Niktimvo collaboration income, while broader-use trials and two early candidates extend the oncology pipeline.
Commercializes two FDA-approved medicines while testing them in earlier treatment settings and additional diseases. Revuforj (revumenib), an oral menin inhibitor, treats relapsed or refractory acute leukemia with a KMT2A translocation and certain acute myeloid leukemia with an NPM1 mutation. Niktimvo (axatilimab-csfr), a CSF-1R-blocking antibody, treats chronic graft-versus-host disease after prior systemic therapies.
Manages Revuforj sales through internal resources and third parties. Incyte leads Niktimvo commercialization; the partners share U.S. profit and loss equally, while Incyte holds commercial rights elsewhere. Pipeline work includes broader uses for both medicines plus SNDX-4321 and SNDX-62122.
Operates as one segment from New York. Revenue is concentrated in these medicines; manufacturing is outsourced, and execution depends on regulators, reimbursement, licensed intellectual property, contract manufacturers, and the Incyte collaboration.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 21, 2026 | UBS | Reiterate | Rating: —Target: $38 | Target: $33 |
| Aug 5, 2026 | H.C. Wainwright | Target | Target: $40 | Target: $38 |
| Jun 12, 2026 | Guggenheim | Target | Target: — | Target: $31 |
| Jun 3, 2026 | H.C. Wainwright | Target | Target: $33 | Target: $40 |
| May 4, 2026 | Stifel Nicolaus | Target | Target: $45 | Target: $46 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $547.9M · Total debt $589.4M · Total assets $703.7M · Shareholders' equity $15.1M
- Revenue
- $72.8M
- Operating income
- −$40.0M
- Net income
- −$49.4M
No dividends on record.
| Institutions | 121.97% | 108.92M shares | |
|---|---|---|---|
| 254 holders · as of Jun 30, 2026 | |||
| Insiders | 1.80% | 1.60M shares | |
| 11 holders · as of Jul 9, 2026 | |||
| Adds to | 123.77% | ||
89.30M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 123.77%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.10% | 9.02M | as of Jun 30, 2026 |
Kynam Capital Management, LPInstitution | 9.02% | 8.05M | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 6.56% | 5.86M | as of Jun 30, 2026 |
State Street CorpInstitution | 6.34% | 5.66M | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 4.53% | 4.05M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 8, 2026 | Michael A. Metzger | director, officer: Chief Executive Officer | −32,375 | $24.24 |
| Jun 12, 2026 | Nicholas A.J. Botwood | officer: Head of R&D, CMO | −31,235 | $18.14 |
| Jun 11, 2026 | Nicholas A.J. Botwood | officer: Head of R&D, CMO | −34,280 | $18.00 |
| Jun 1, 2026 | Michael A. Metzger | director, officer: Chief Executive Officer | −6,847 | $18.99 |
| Jun 1, 2026 | Keith A. Goldan | officer: Chief Financial Officer | −1,177 | $18.99 |
- Kura
Second FDA-approved menin inhibitor with same R/R NPM1-mutated AML label
- Sanofi (ADR)
Rezurock holds identical cGVHD label to Niktimvo (≥2 prior lines)
- Incyte
Partner on Niktimvo yet upstream cGVHD competitor via Jakafi
- Bristol-Myers Squibb
Diversified biopharma with hematology franchise spanning AML and GVHD prevention
- Mesoblast (ADR)
First MSC therapy approved for pediatric steroid-refractory acute GVHD
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals | $17.91 | −1.51% | $1.61B | — | — | 6.4 | +91.8% |
| Kura | $11.42 | −2.69% | $1.04B | — | — | 13.5 | +36.5% |
| Sanofi (ADR) | $41.74 | −1.81% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Incyte | $125.84 | −0.86% | $25.73B | 16.2 | 52.1 | 4.4 | +37.7% |
| Bristol-Myers Squibb | $61.87 | −0.61% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Mesoblast (ADR) | $15.50 | −2.64% | $2.06B | — | — | 17.1 | +391.8% |
| Median | 16.2 | 30.9 | 4.4 | +36.5% |